Drug Metabolism and Biotransformation
Drug metabolism, or biotransformation, is the set of enzyme-catalysed chemical reactions by which the body converts drugs and other foreign compounds (xenobiotics) into different molecules called metabolites. These reactions usually make a lipophilic drug more water-soluble so it can be excreted, and they can inactivate a drug, sometimes activate a prodrug, and occasionally generate reactive species that contribute to toxicity. As an area of medicinal and pharmaceutical chemistry, it links the chemical structure of a molecule to its biological fate.
Definition
Drug metabolism (biotransformation) is the enzymatic conversion of a drug into one or more chemically distinct metabolites, typically increasing hydrophilicity to facilitate elimination and altering the parent compound's pharmacological and toxicological activity.
Scope
The area orients the reader to how the body chemically transforms drugs: the classical division into Phase I (functionalisation) and Phase II (conjugation) reactions, the principal enzyme families that catalyse them, the genetic and environmental factors that make metabolism vary between people, and the formation of toxic metabolites. It frames metabolism as a chemical and pharmacological topic underlying drug design, absorption-distribution-metabolism-excretion (ADME) science, and drug-interaction prediction; it is not clinical dosing guidance.
Sub-topics
Core questions
- How does the body chemically transform a drug into metabolites that can be excreted?
- What distinguishes Phase I functionalisation reactions from Phase II conjugation reactions?
- Which enzyme families carry out biotransformation, and what determines their activity?
- Why does the rate and route of metabolism differ so widely between individuals?
- When does metabolism inactivate a drug, activate a prodrug, or create a toxic metabolite?
Key concepts
- Biotransformation
- Phase I (functionalisation) reactions
- Phase II (conjugation) reactions
- Cytochrome P450 enzymes
- First-pass metabolism
- Prodrug activation
- Reactive (toxic) metabolites
- Enzyme induction and inhibition
- Pharmacogenetic variability
- Clearance and elimination
Mechanisms
Biotransformation is conventionally organised into two stages. Phase I reactions introduce or unmask a functional group (for example a hydroxyl, amino, or carboxyl group) through oxidation, reduction, or hydrolysis, most often catalysed by cytochrome P450 (CYP) enzymes; these reactions modestly increase polarity and frequently inactivate the drug, though they may also generate reactive intermediates. Phase II reactions then conjugate the parent drug or its Phase I metabolite with an endogenous molecule such as glucuronic acid, sulfate, glutathione, or an acetyl or methyl group, generally producing a far more water-soluble, readily excreted product. The balance among these enzyme systems, together with their induction or inhibition by other drugs and their genetically determined activity, governs how much active drug reaches the systemic circulation and how long it persists.
Clinical relevance
Understanding biotransformation explains why drugs differ in how long they act, why two drugs given together can alter each other's levels through shared enzymes, and why some patients metabolise a drug much faster or slower than others. It underpins the design of prodrugs and metabolically stable molecules and the interpretation of drug-interaction and pharmacogenetic studies. This area describes the chemical and biological basis of these phenomena and is not a source of individualised dosing or treatment instructions.
Evidence & guidelines
Knowledge in this area rests on in vitro enzyme and microsome studies, animal and human pharmacokinetic data, and structure-activity analyses, synthesised in narrative reviews and textbooks of drug metabolism. Regulatory guidance on drug-metabolism and drug-interaction studies (for example from the US FDA and EMA) and pharmacogenetic dosing frameworks (such as those of CPIC and the Dutch Pharmacogenetics Working Group) translate this science into expectations for drug development and prescribing, but the area entry itself is an educational overview rather than a clinical protocol.
History
The recognition that the body chemically alters drugs dates to nineteenth-century studies of substances such as benzoic acid, but modern drug metabolism took shape in the mid-twentieth century with R. T. Williams' conceptual division of biotransformation into functionalisation and conjugation reactions. The discovery and characterisation of the cytochrome P450 enzymes from the 1960s onward, and later the molecular cloning of the human CYP and conjugating enzyme families, turned the field into a mechanistic chemical science central to drug discovery and ADME prediction.
Key figures
- F. Peter Guengerich
- Bernard Testa
- Grant R. Wilkinson
- B. Kevin Park
Related topics
Seminal works
- wilkinson-2005
- guengerich-2001
Frequently asked questions
- What is the difference between drug metabolism and biotransformation?
- The two terms are used interchangeably for the enzyme-catalysed chemical conversion of a drug into metabolites; 'biotransformation' emphasises the chemical change, while 'drug metabolism' is the common pharmacological label.
- Does metabolism always inactivate a drug?
- No. Metabolism usually reduces activity and aids excretion, but it can convert an inactive prodrug into its active form, or generate a reactive metabolite that contributes to toxicity.